Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes

Abstract

Background Visfatin is a multifaceted protein that plays an important role in regulating a variety of physiological and pathological processes, including obesity, diabetes and cardiovascular disease. However, circulating visfatin levels in atherosclerosis plaque progression in patients with type 2 diabetes, or its association with the vascular territory affected remain unclear. Methods We evaluated the relationship between visfatin levels and carotid or femoral artery atherosclerosis in Chinese patients with type 2 diabetes. Serum levels of visfatin were measured by enzyme-linked immunosorbent assay (ELISA) in 97 inpatients with type 2 diabetes. Carotid and/or femoral atherosclerotic plaques were detected by B-mode ultrasound. Results Serum visfatin levels were elevated in the group with atherosclerotic plaques compared to the control group without plaques [0.68 (0.46–1.58) versus 0.45 (0.23–0.76) ng/mL, respectively, P = 0.0002]. Patients with carotid plaques showed higher visfatin levels than those with or without femoral plaques. Pearson’s correlation analysis showed that serum visfatin levels were positively correlated with waist circumference ( r = 0.226, P = 0.029), waist-hip ratio ( r = 0.221, P = 0.032), TG ( r = 0.222, P = 0.030) and number of plaques ( r = 0.275, P = 0.009). Logistic regression analysis showed that a higher serum visfatin level was an independent predictor for the presence of atherosclerotic plaques. Conclusions In conclusion, among patients with T2DM, serum visfatin levels were elevated in those with atherosclerotic plaques, especially in patients with carotid atherosclerotic plaques. Serum visfatin may serve as a predictor of atherosclerotic plaques in patients with T2DM. Electronic supplementary material The online version of this article (10.1186/s13098-019-0455-5) contains supplementary material, which is available to authorized users.

Control of Adipose Cell Browning and Its Therapeutic Potential

“…Visfatin, also known as nicotinamide phosphoribosyl-transferase (Nampt), is an adipocytokine secreted by adipocytes, macrophages, and inflamed endothelial tissue. High levels of visfatin are observed in patients with obesity, type 2 diabetes mellitus, chronic inflammatory conditions and cancer, and an association between serum visfatin levels and cardiovascular disease has recently been observed in patients with type 2 diabetes [ 123 , 124 , 125 ]. Moreover, BAT exhibits multiple cytoplasmic lipid inclusions and numerous mitochondria.…”

Blood Adipokins in Young People with Early Ischemic Heart Disease on the Background of Abdominal Obesity

“…Zheng и соавт. [26] показали, что уровни в крови висфатина у пациентов с СД и с АСБ в сонной артерии были выше, чем у пациентов с СД без АСБ. Результаты логистического регрессионного анализа показали, что более высокий уровень висфатина в крови был независимым предиктором наличия АСБ.…”

The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review

“…Pearson's correlation analyses suggested that the serum levels of visfatin positively correlated with waist circumference, waist hip index, TGs, and the number of plaques. Logistic regression analysis revealed that a higher level of visfatin in serum is an independent predictor of the presence of atherosclerotic plaques [97].…”